FGFR aberrations
HER2-positive
PFS and OS
breast cancer with brain metastasis
circulating tumor DNA
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
10
2019
accepted:
05
02
2020
entrez:
6
6
2020
pubmed:
6
6
2020
medline:
6
6
2020
Statut:
epublish
Résumé
The survival status of patients with breast cancer and brain metastasis (BCBM) receiving current treatments is poor. We designed a real-world study to investigate using patients' clinical and genetic aberrations to forecast the prognoses of BCBM patients. We recruited 146 BCBM patients and analyzed their clinical features to evaluate the overall survival (OS). For genetic testing, 30 BCBM and 165 non-brain-metastatic (BM) metastatic breast cancer (MBC) patients from Hunan Cancer Hospital, and 86 BCBM and 1416 non-BM MBC patients from the Geneplus database who received circulating tumor DNA testing, were compared and analyzed. Ki67 >14% and >3 metastatic brain tumors were significant risk factors associated with poor OS, while chemotherapy and brain radiotherapy were beneficial factors for better OS. Compared with non-BM MBC patients, BCBM patients had more fibroblast growth factor receptor ( A group of genetic events, including
Sections du résumé
BACKGROUND
BACKGROUND
The survival status of patients with breast cancer and brain metastasis (BCBM) receiving current treatments is poor.
METHOD
METHODS
We designed a real-world study to investigate using patients' clinical and genetic aberrations to forecast the prognoses of BCBM patients. We recruited 146 BCBM patients and analyzed their clinical features to evaluate the overall survival (OS). For genetic testing, 30 BCBM and 165 non-brain-metastatic (BM) metastatic breast cancer (MBC) patients from Hunan Cancer Hospital, and 86 BCBM and 1416 non-BM MBC patients from the Geneplus database who received circulating tumor DNA testing, were compared and analyzed.
RESULTS
RESULTS
Ki67 >14% and >3 metastatic brain tumors were significant risk factors associated with poor OS, while chemotherapy and brain radiotherapy were beneficial factors for better OS. Compared with non-BM MBC patients, BCBM patients had more fibroblast growth factor receptor (
CONCLUSION
CONCLUSIONS
A group of genetic events, including
Identifiants
pubmed: 32499836
doi: 10.1177/1758835920915305
pii: 10.1177_1758835920915305
pmc: PMC7243401
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835920915305Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Nat Rev Cancer. 2017 May;17(5):318-332
pubmed: 28303906
Am J Hum Genet. 2016 Mar 3;98(3):579-587
pubmed: 26942290
Clin Breast Cancer. 2013 Jun;13(3):167-72
pubmed: 23218471
J Neurooncol. 2016 May;127(3):407-14
pubmed: 26909695
Breast Cancer Res Treat. 2014 Feb;143(3):435-46
pubmed: 24398778
J Clin Invest. 2012 Jun;122(6):2153-64
pubmed: 22585574
Ann Oncol. 2011 Mar;22(3):625-30
pubmed: 20724575
Gut. 2018 Aug;67(8):1484-1492
pubmed: 28790159
Clin Cancer Res. 2011 Jul 15;17(14):4834-43
pubmed: 21768129
Br J Cancer. 2012 Jan 3;106(1):25-31
pubmed: 22127284
Clin Cancer Res. 2011 Oct 1;17(19):6130-9
pubmed: 21953501
Br J Cancer. 2010 Mar 16;102(6):995-1002
pubmed: 20179708
Lancet Oncol. 2018 Jul;19(7):880-888
pubmed: 29804905
Science. 2012 Sep 7;337(6099):1231-5
pubmed: 22837387
Lung Cancer. 2014 Jan;83(1):83-9
pubmed: 24183471
Oncotarget. 2017 Jun 6;8(23):38056-38060
pubmed: 28445137
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Ann Oncol. 2011 Dec;22(12):2597-603
pubmed: 21427063
Semin Oncol. 2015 Dec;42(6):801-19
pubmed: 26615127
Breast Cancer Res. 2007;9(2):R23
pubmed: 17397528
Curr Neurol Neurosci Rep. 2017 Apr;17(4):37
pubmed: 28326470
Ann Oncol. 2003 Jul;14(7):1072-7
pubmed: 12853349
Am J Pathol. 2005 Oct;167(4):913-20
pubmed: 16192626
Exp Hematol Oncol. 2015 Nov 24;4:33
pubmed: 26605131
Ann Oncol. 2014 Mar;25(3):552-63
pubmed: 24265351
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Oncogene. 2007 Nov 1;26(50):7158-62
pubmed: 17525745
Lancet. 2016 Feb 6;387(10018):545-557
pubmed: 26615328
J Neurooncol. 2013 Sep;114(2):181-9
pubmed: 23743596
EBioMedicine. 2018 Jun;32:111-118
pubmed: 29807833
Mol Cancer Ther. 2012 Oct;11(10):2301-5
pubmed: 22879364
Int J Mol Sci. 2016 Sep 13;17(9):
pubmed: 27649142
J Clin Oncol. 2019 May 1;37(13):1081-1089
pubmed: 30860945
J Clin Oncol. 2009 Nov 1;27(31):5278-86
pubmed: 19770385
J Mol Diagn. 2017 Jul;19(4):525-536
pubmed: 28502728
Ann Oncol. 2015 Aug;26(8):1715-22
pubmed: 25851626
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Front Oncol. 2018 May 24;8:161
pubmed: 29881714
Cancer. 2008 Nov 15;113(10):2638-45
pubmed: 18833576
Curr Opin Oncol. 2012 Nov;24(6):679-86
pubmed: 22820413
Medicine (Baltimore). 2018 Apr;97(15):e0349
pubmed: 29642175
J Clin Oncol. 2004 Sep 1;22(17):3608-17
pubmed: 15337811
Ann Oncol. 2014 Jan;25(1):32-40
pubmed: 24225019
Eur J Cancer. 2017 Oct;84:141-148
pubmed: 28810186
Nat Med. 2016 Jul;22(7):723-6
pubmed: 27270588
Int J Cancer. 2017 May 15;140(10):2344-2350
pubmed: 28205231
Cancer Res. 1997 Mar 1;57(5):963-9
pubmed: 9041202
Cancer Res. 2010 Mar 1;70(5):2085-94
pubmed: 20179196
Oncol Lett. 2018 Jun;15(6):8206-8214
pubmed: 29805554
Clin Cancer Res. 2016 Jan 1;22(1):259-67
pubmed: 26373574
Oncologist. 2008 Oct;13(10):1114-9
pubmed: 18849320
Mol Cancer Ther. 2012 Mar;11(3):690-9
pubmed: 22238366
Tumori. 2015 Mar 20;101(1):e9-e12
pubmed: 25702650
Acta Neuropathol. 2016 Jun;131(6):847-63
pubmed: 26920151